Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | TKT | P29401 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525326 | 1.00 | TRPV4 (0.52) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL28507373 | 0.84 | TRPV4 (0.48) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL1259004 | 0.84 | TKT (0.55) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL1743280 | 0.84 | TKT (0.39) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL21377439 | 0.84 | CSF1R (0.53) | KDM1AMAOAMAOBTRPV1NAMPT | |
| SCHEMBL28783425 | 0.83 | KDM1A (0.45) | TRPV4KDM1AMAOAMAOBKCNQ3 | |
| SCHEMBL14028936 | 0.81 | TKT (0.49) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL31067892 | 0.81 | TKT (0.49) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL7993760 | 0.80 | TKT (0.48) | TRPV4TKTDAOKDM1AMAOA | |
| SCHEMBL317731 | 0.79 | TRPV4 (0.52) | TRPV4TKTDAOKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530396-A | Modified acrylic emulsion and application thereof | 中山市新谷新材料有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-117088878-A | High-activity Wnt pathway inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-117088876-A | High-activity Wnt pathway inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-105829294-B | The quinolyl conditioning agent of ROR- γ-T being connect with methylene | 詹森药业有限公司 | 2018-11-09 | — | — | CN | claimed |
| CN-105829294-A | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | 詹森药业有限公司 | 2016-08-03 | — | — | CN | claimed |
| CN-105209453-A | Methylene linked quinolinyl modulators of ROR-gamma-T | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | claimed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORP (US) | 2025-09-18 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | GENZYME CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
| CN-1179952-C | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors | ʷ | 2004-12-15 | — | — | CN | disclosed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1451161-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | Merck Sharp & Dohme Limited (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048132-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| CN-1418199-A | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | TRPV4 2913/4885TKT 2111/4885DAO 643/4885 |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | TRPV4 3797/4885TKT 4579/4885DAO 3426/4885 |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | NTRK1, NGF, NTRK2 | TRPV4 1778/4885TKT 195/4885DAO 3493/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | TRPV4 4510/4885TKT 3844/4885DAO 4037/4885 |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | TRPV4 2821/4885TKT 3830/4885DAO 874/4885 |
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | TRPV4 1778/4885TKT 195/4885DAO 3493/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | TRPV4 3064/4885TKT 2371/4885DAO 4138/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPV4 4185/4885TKT 376/4885DAO 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.